Group items tagged

The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement (U01) applications that propose studies to enhance pre-clinical in vitro and in vivo testing of NCI-prioritized molecularly targeted anti-cancer agents for use with radiation therapy combined with systemic chemotherapy. These studies should generate validated high-quality preclinical data on the effects of molecular therapeutics when added to standard-of-care therapies for solid tumors. The specific purpose is to provide a more rational basis for prioritizing those NCI-supported investigational new drugs or agents (INDs) most likely to have clinical activity with chemo-radiotherapy. The overall goal is to accelerate the pace at which combined modality treatments with greater efficacy are identified and incorporated into standard practices for treatments of patients with solid tumors.

The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement (U01) applications that propose studies to enhance pre-clinical in vitro and in vivo testing of NCI-prioritized molecularly targeted anti-cancer agents for use with radiation therapy combined with systemic chemotherapy. These studies should generate validated high-quality preclinical data on the effects of molecular therapeutics when added to standard-of-care therapies for solid tumors. The specific purpose is to provide a more rational basis for prioritizing those NCI-supported investigational new drugs or agents (INDs) most likely to have clinical activity with chemo-radiotherapy. The overall goal is to accelerate the pace at which combined modality treatments with greater efficacy are identified and incorporated into standard practices for treatments of patients with solid tumors.

This Funding Opportunity Announcement (FOA) invites applications that focus on clarifying the relationship between delirium and Alzheimer's disease and related dementias (ADRD). Specifically sought is research focusing on understanding why persons with ADRD are at increased risk to develop delirium, often with a worse prognosis compared to those without antecedent ADRD, and why patients who experience delirium are at higher risk to develop subsequent short- and/or long-term mild cognitive impairment or ADRD, often with an accelerated rate of cognitive decline compared to those without preceding delirium. Relevant research projects may focus on, but are not limited to, those that A) provide insight into possible common, sequential, causative, contributory and/or synergistic pathways underlying both ADRD and delirium, B) elucidate mechanisms that lead to the development of delirium against the background of aging and/or neurodegeneration, with particular emphasis on use of appropriate animal models, C) identify risk factors for the onset and/or progression of delirium in those with ADRD and vice versa, D) diagnose and assess one condition in the setting of the other, E) identify putative phenotypes of patients with co-existing ADRD and delirium, or F) test pharmacologic and/or non-pharmacologic strategies to prevent, treat, or reduce the impact of delirium in patients with ADRD and vice versa. Research supported by this FOA is intended to provide mechanistic insight to improve risk assessment, diagnosis, phenotyping, prevention, and management approaches for both delirium and ADRD.

NIDILRR proposes to fund two Disability and Rehabilitation Research Projects of three years each to conduct research on opioid use disorder among people with disabilities. Each grant will be funded up to $500,000. Topic of interest include: 1) Systematic review of existing literature on opioid-use disorder and people with disabilities; 2) Prevalence estimates and patterns of opioid use disorder treatment for people with disabilities; 3) Factors associated with increased risk for opioid use disorder; 4) Factors associated with improved access to treatment for opioid use disorder; 5) Interventions that contribute to improved outcomes; and 6) Effects of government policies and programs on access to treatment for people with disabilities who have opioid-use disorders.

The OPORP Orthotics and Prosthetics Outcomes Research Award (OPORA) is being offered for the first time in FY14. It is intended to support research that evaluates the comparative effectiveness of and functional outcomes associated with prosthetic and orthotic clinical interventions and/or other rehabilitation interventions for Service Members and Veterans who have undergone limb salvage or limb amputation. The goal is to improve our understanding of and ultimately advance the implementation of the most effective prescriptions for prosthetic and orthotic devices, treatment, rehabilitation, and secondary health effect prevention options for patients, clinicians, other caregivers, and policymakers. Proposed projects should be designed to provide outcomes data regarding orthotic and prosthetic devices, and/or related clinical interventions and must include the anticipated effect on patient care metrics. Collaboration with military researchers and clinicians is encouraged, as are joint Department of Defense (DoD)-VA studies, including longitudinal outcome studies. Studies are sought that: * Compare different patient care approaches. * Include patient-centric outcome assessments. * Have the potential to generate new knowledge that can be developed into new clinical practice guidelines, and/or new prescription algorithms for prosthetic and orthotic devices. * Have the potential to develop new technology for improved prosthetic and orthotic devices, therefore improving patient outcomes. * Provide information on quality of life, reintegration, and/or return to duty/return to work as it pertains to those patients who use a prosthetic or orthotic device due to limb trauma. All applications must demonstrate direct relevance to Service Members and Veterans with traumatic extremity injury and/or amputation using prosthetics and orthotic devices. Examples of studies that are appropriate for submission to the FY14 OPORA include, but are not limited to, examination of the

The purpose of this notice of funding opportunity is to identify and implement innovative strategies to better engage, detect, and manage glaucoma and other eye diseases among vulnerable populations, in community-based settings, for replication and scaling in the US. This NOFO will be accomplished with two components; Component A: Community-Based Interventions with Vulnerable Populations and Component B: Coordinating Center to provide logistics and support to the research study. Glaucoma is the leading cause of irreversible blindness among African Americans and the second leading cause of blindness worldwide. An estimated 2.2 to 2.7 million people in the United States have the disease. Due to its asymptomatic nature, half of people with glaucoma are unaware of their condition, increasing the severity of the disease. However, once detected, appropriate treatment and management can slow glaucoma progression and preserve the remaining vision, but cannot restore lost vision. Given the low general population prevalence of glaucoma, broad general population screening appears not to be cost-effective, and the marginal results from glaucoma screenings in high-risk population, it is reasonable to reach out to groups with higher prevalence (African Americans over age 40, Asians, older people [aged 65+ years] especially older Hispanics, those with a family history of glaucoma, and those with diabetes).

The National Council on Disability (NCD) will seek proposals for a report series on bioethics and disability. The findings in these reports primarily serve to assist policymakers, including the White House and Congress, with the insight needed to make policy decisions designed to improve medical decision-making regarding persons with disabilities. The reports will also provide state legislatures, medical associations and educators, and persons with disabilities and those who support them, with an understanding of policy, legislation, and initiatives that impact their lives. The report series will examine policies and practices related to the availability of medical interventions and life-saving medical care for persons with disabilities. It will examine five specific areas where disability and bioethics intersect, with a focus on how a person's disability impacts medical decisions, including decisions to provide life-saving care.

The primary purpose of this solicitation is to support highly interactive, multi-disciplinary teams, whose research efforts are focused on large-scale discovery of T cell immune epitopes associated with infectious or autoimmune diseases, and rejection of, or tolerance to, transplanted cells/organs/tissues. The discovery of epitopes associated with T cell responses to commensals and how they may be altered by the inflammatory state will also be supported by this solicitation. Validation of these epitopes and defining their role in immune protection or immune-mediated pathogenesis in humans is required. Investigators may include development/refinement of T cell epitope prediction tools as part of their research plan. It is anticipated that the multi-disciplinary teams will minimally include immunologists with the appropriate expertise in epitope identification and validation, and either microbiologists and/or virologists with expertise in the target pathogen(s), clinicians with expertise in the target autoimmune diseases, or clinicians with expertise in transplantation, as appropriate. This program will not support studies related to HIV/AIDS, or allergen epitopes, including those which are infection-related.

The B2B was launched by NHLBI in 2009 as a novel approach to break through the major barriers of translational research, identify the causes of human congenital heart disease, and ultimately improve outcomes for individuals with congenital heart disease. The B2B strategy is to accelerate translation of scientific discovery into clinical practice through collaborations among basic, translational, and clinical researchers. The CDDRC and PCGC interact with each other, and with the NHLBI Pediatric Heart Network (PHN) to encourage translation of results from basic science to clinical research, and to provide clinical input on pressing needs for basic and translational research. The goal of the CDDRC is to accelerate discovery of the genetic etiology and biologic pathways associated with cardiovascular development and congenital heart disease by facilitating access to and querying of annotated data from cardiovascular development studies. The CDDRC will facilitate analysis of candidate genes and variants associated with CHD by assembling the data output from previous funding cycles of the Cardiovascular Development Consortium (CvDC), plus external datasets, into a queryable data repository complete with computational tools. The product of the CDDRC would, by the end of the project period, be a coordinated and interoperable suite of harmonized datasets, computational tools, and links to model organism databases that could be inserted as a functional module into the NHLBI DataSTAGE platform.

The Department of Education is issuing a notice inviting applications for new awards for fiscal year (FY) 2018 for Personnel Development to Improve Services and Results for Children with Disabilities-Associate Degree Preservice Program Improvement Grants to Support Personnel Working with Young Children with Disabilities

Research!America is pleased to announce an exciting new program to introduce and engage early-career scientists in research advocacy and science policy. The 2013 Research!America Advocacy Academy is a unique opportunity for postdoctoral fellows in the health and biomedical sciences to learn about how to best incorporate advocacy and effective communications into their role as a scientist. The 2013 class of up to 12 Research!America advocates will participate in a two-day Washington, DC, program from September 11-12, 2013. Participants will learn about the federal budget and appropriations process, tools for effective science communication and outreach as well as how to engage with elected representatives on scientific and research issues. The program includes visiting Capitol Hill to meet with policy makers and congressional staff members, providing participants with a first-hand experience advocating for health research. Rounding out this unique Washington experience, participants will attend Research!America's National Health Research Forum where top leaders in government, industry, academia and patient organizations engage in moderated conversations on issues of importance to the research ecosystem. Upon completion of the program, participants will become Science Advocates for Research!America. Advocates will remain engaged with Research!America staff, receive ongoing action alerts and learn about ways to involve their home institution's research community in effective science advocacy. All travel expenses (transportation, lodging and meals) will be provided and arranged by Research!America through an educational grant provided by Pfizer. This year's program is limited to 12 exceptional postdoctoral researchers with a dedicated interest in becoming active advocates for science.

he U.S. Congress provides funds to CDC for programmatic support and procurement of vaccines critical to the success of the global initiatives for polio eradication and measles mortality reduction. The purpose of the program is to support the US Government-endorsed Global Polio Eradication Initiative, Global Measles Initiative, and the Global Immunization Vision and Strategy (GIVS) of which UNICEF is a key partner. Other key partners include CDC, World Health Organization (WHO), the Pan American Health Organization (PAHO), Rotary International, American Red Cross, and the UN Foundation. UNICEF, in conjunction with CDC, will provide programmatic assistance and vaccines for supplemental immunization activities (SIAs) in priority countries as well as strengthening of routine immunization delivery systems and capacities in developing countries to achieve globally agreed goals for disease eradication, elimination and reduction. Additionally this agreement may be used to support activities to address other global health priorities in line with CDC goals. Under this agreement, UNICEF will collaborate with CDC, World Health Organization (WHO), Rotary International, other partner agencies and national governments, for implementation of strategies to achieve the globally agreed goals of polio eradication, measles mortality reduction and elimination, and control of other vaccine preventable diseases (VPD), including identification and prioritization of country vaccine and programmatic assistance needs.

he U.S. Congress provides funds to CDC for programmatic support and procurement of vaccines critical to the success of the global initiatives for polio eradication and measles mortality reduction. The purpose of the program is to support the US Government-endorsed Global Polio Eradication Initiative, Global Measles Initiative, and the Global Immunization Vision and Strategy (GIVS) of which UNICEF is a key partner. Other key partners include CDC, World Health Organization (WHO), the Pan American Health Organization (PAHO), Rotary International, American Red Cross, and the UN Foundation. UNICEF, in conjunction with CDC, will provide programmatic assistance and vaccines for supplemental immunization activities (SIAs) in priority countries as well as strengthening of routine immunization delivery systems and capacities in developing countries to achieve globally agreed goals for disease eradication, elimination and reduction. Additionally this agreement may be used to support activities to address other global health priorities in line with CDC goals. Under this agreement, UNICEF will collaborate with CDC, World Health Organization (WHO), Rotary International, other partner agencies and national governments, for implementation of strategies to achieve the globally agreed goals of polio eradication, measles mortality reduction and elimination, and control of other vaccine preventable diseases (VPD), including identification and prioritization of country vaccine and programmatic assistance needs. 

The Physical Oceanography Program supports research on a wide range of topics associated with the structure and movement of the ocean, with the way in which it transports various quantities, with the way the ocean's physical structure interacts with the biological and chemical processes within it, and with interactions between the ocean and the atmosphere, solid earth and ice that surround it.

The SCIMS program is designed to provide a multidisciplinary system of rehabilitation care specifically to meet the needs of individuals with SCI. To be eligible for a SCI Model Systems grant, an applicant institution must encompass a continuum of care for people with SCI, including emergency medical services, acute care services, acute medical rehabilitation services, and post-acute services. For purposes of this program, SCI is defined as a clinically discernible degree of neurologic impairment of the spinal cord following a traumatic event. NIDILRR currently supports 14 SCIMS centers through this program. The funding for these Centers is primarily used to conduct SCI research and to collect and send data to the SCIMS longitudinal database. SCIMS Centers will be funded at varying amounts up to the maximum award based on the numbers of subjects eligible for follow-up in the existing SCIMS longitudinal database. Existing centers with significantly larger numbers of subjects will receive higher funding within the specified range, as determined by NIDILRR after the applicant is selected for funding. Applicants provide detailed budgets for each research project and for data collection costs associated with the longitudinal database. Funding will be determined individually for each successful applicant, up to the maximum allowed, based upon the documented workload associated with the follow-up data collection, the other costs of the grant, and the overall budgetary limits of the program

The purpose of the AETC NCCC is to supply health care providers with a national resource to obtain timely and appropriate responses to clinical questions relating to: 1) the treatment of people living with HIV (PLWH) and those at high risk for HIV infection; 2) health care worker exposure to HIV and other blood borne pathogens (e.g., viral hepatitis); 3) the treatment of pregnant women living with HIV, and their exposed infants, and a perinatal referral service to connect them with HIV-experienced care providers; and 4) PLWH with behavioral health and/or substance abuse issues. 

Ohio is home to approximately 26,000 individuals living with paralysis as a result of a Spinal Cord Injury (SCI). According to the National SCI Statistical Center 66% of those individuals remain unemployed with each expected to manage lifetime healthcare costs of $1-3M. This represents a significant cost to the state and also imposes a severe burden on the quality of life for those living with this impairment. While there is research in pursuit of improved treatments to ameliorate the effects of paralysis, the field is significantly underfunded relative to similarly sized patient populations or disease with similar lifetime healthcare costs. While the scientific disciplines of neuroscience and biomedical engineering are making progress toward the development of new treatments, there is a lack of systematic and especially localized effort to guide these advances representative of the various stakeholders. The research funded through this process is specifically targeted to advance and accelerate the development of innovative treatments, product innovation and rehabilitative efforts that lead to the functional improvement of people living with spinal cord injuries. Research topics may include, but are not limited to, discovery science, pharmaceutical development, medical device design and implementation, and the development of novel rehabilitative approaches and techniques.

The goal of this NOFO is to provide comprehensive HIV services in Zambia to the general population in areas of high HIV prevalence; and priority populations (PPs), including people living with HIV (PLHIV), adolescent girls and young women (AGYW), men, couples, pregnant women, prisoners, and key populations (KPs). Services to be provided will include: community-based HIV testing services (HTS); HIV prevention services (risk reduction counseling,gender norms, and links to post gender-based violence (GBV) care); TB prevention and treatment, and community based antiretroviral therapy (ART). These services will be linked with community health care facilities. The recipient(s) will work closely with the relevant District Medical Offices (DMOs) selected in consultation with CDC Zambia. To ensure efficiencies and program effectiveness, this NOFO will support activities that complement activities supported by the Zambian government and partners with full transition to the local districts by the end of year five.

The AAAS Early Career Award for Public Engagement with Science, established in 2010, recognizes early-career scientists and engineers who demonstrate excellence in their contribution to public engagement with science activities. A monetary prize of $5,000, a commemorative plaque, complimentary registration to the AAAS Annual Meeting, and reimbursement for reasonable hotel and travel expenses to attend the AAAS Annual Meeting to receive the prize are given to the recipient. Nominee must be an early-career scientist or engineer in academia, government or industry actively conducting research in any scientific discipline (including social sciences and medicine).  "Early career" is defined as an individual who has been in his/her current field for less than seven years and pre-tenure or job equivalent. Post-doctoral students are eligible for this award. Nominee will have demonstrated excellence in his/her contribution to public engagement with science activities, with a focus on interactive dialogue between the individual and a non-scientific, public audience(s). Types of public engagement activities might include: informal science education, public outreach, public policy, and/or science communication activities, such as mass media, public dialogue, radio, TV and film, science café, science exhibit, science fair, and social and online media.

The purpose of this FOA is to support innovative interdisciplinary, multi-institute research that will lead to the identification and validation of molecular mechanisms relevant to human biology that contribute to tau toxicity associated with Frontotemporal Degeneration (FTD). It is anticipated that this research will also contribute to tool development that can be applied to target validation in FTD clinical trials.Applications must include an administrative core, a scientific governance structure, a minimum of three research projects with milestone plans, resource core(s) that support the basic research efforts of at least two proposed research projects, a data coordination core that will facilitate the distribution of data generated through the Center without Walls with the broad research community and a human biology validation core that will support the validation of mechanisms identified and resources developed under this FOA. Synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2015 update to the National Plan to Address Alzheimer's Disease.

The purpose of this FOA is to support innovative interdisciplinary, multi-institute research that will lead to the identification and validation of molecular mechanisms relevant to human biology that contribute to tau toxicity associated with Frontotemporal Degeneration (FTD). It is anticipated that this research will also contribute to tool development that can be applied to target validation in FTD clinical trials.Applications must include an administrative core, a scientific governance structure, a minimum of three research projects with milestone plans, resource core(s) that support the basic research efforts of at least two proposed research projects, a data coordination core that will facilitate the distribution of data generated through the Center without Walls with the broad research community and a human biology validation core that will support the validation of mechanisms identified and resources developed under this FOA. Synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2015 update to the National Plan to Address Alzheimer's Disease.

The purpose of this funding opportunity announcement (FOA) is to 1) expand the collection of clinical data and biological specimens in the NINDS Parkinsons Disease Biomarkers Program (PDBP), a community research resource, to include data from patients with Lewy Body Dementias (including Dementia with Lewy Bodies and Parkinson's Disease with Dementia), and 2) to support hypothesis-driven clinical research to discover biomarkers that will improve the efficiency and outcome of Phase II clinical trials for the Lewy Body dementias and to provide an expansion of this existing research resource center for dissemination of information and access by the scientific community for further advancing research in this field. Applications may include both of these goals if justified.

The purpose of this funding opportunity announcement (FOA) is to 1) expand the collection of clinical data and biological specimens in the NINDS Parkinsons Disease Biomarkers Program (PDBP), a community research resource, to include data from patients with Lewy Body Dementias (including Dementia with Lewy Bodies and Parkinson's Disease with Dementia), and 2) to support hypothesis-driven clinical research to discover biomarkers that will improve the efficiency and outcome of Phase II clinical trials for the Lewy Body dementias and to provide an expansion of this existing research resource center for dissemination of information and access by the scientific community for further advancing research in this field. Applications may include both of these goals if justified.

One of JDRF's therapeutic goals is to restore beta cell function in type 1 diabetes (T1D) by replacement/transplantation of beta cells/islets. Pancreatic islet transplantation has been efficacious in selected patients in improving metabolic control and quality of life, and in preventing severe hypoglycemia in patients with medically unstable T1D. Despite improvements in cadaveric pancreas procurement, islet isolation, and islet purification, major scientific and technical challenges remain that must be addressed before beta cell replacement could be widely incorporated into the clinical management of established T1D; examples include serious side effects from chronic immunosuppression and the insufficient human islet supply from cadaveric pancreata. JDRF's role is to enable the scientific community to address these challenges with the ultimate goal of developing safe and effective beta cell replacement approaches available to large numbers of individuals with T1D.

One of JDRF's therapeutic goals is to restore beta cell function in type 1 diabetes (T1D) by replacement/transplantation of beta cells/islets. Pancreatic islet transplantation has been efficacious in selected patients in improving metabolic control and quality of life, and in preventing severe hypoglycemia in patients with medically unstable T1D. Despite improvements in cadaveric pancreas procurement, islet isolation, and islet purification, major scientific and technical challenges remain that must be addressed before beta cell replacement could be widely incorporated into the clinical management of established T1D; examples include serious side effects from chronic immunosuppression and the insufficient human islet supply from cadaveric pancreata. JDRF's role is to enable the scientific community to address these challenges with the ultimate goal of developing safe and effective beta cell replacement approaches available to large numbers of individuals with T1D.